Alkylating agents are present in food and tobacco smoke, but are also used in cancer chemotherapy, inducing the DNA lesion O 6 -methylguanine. This critical adduct is repaired by O 6 -methylguanine-DNA methyltransferase (MGMT), resulting in MGMT inactivation and degradation. In the present study, we analyzed the effects of the natural disulfide compound lipoic acid (LA) on MGMT in vitro and in colorectal cancer cells. We show that LA, but not its reduced form dihydrolipoic acid, potently inhibits the activity of recombinant MGMT by interfering with its catalytic Cys-145 residue, which was partially reversible by N-acetyl cysteine. Incubation of HCT116 colorectal cancer cells with LA altered their glutathione pool and caused a decline in MGMT activity. This was mirrored by LA-induced depletion of MGMT protein, which was not attributable to changes in MGMT messenger RNA levels. Loss of MGMT protein coincided with LA-induced autophagy, a process resulting in lysosomal degradation of proteins, including presumably MGMT. LA-stimulated autophagy in a p53-independent manner as revealed by the response of isogenic HCT116 cell lines. Knockdown of the crucial autophagy component beclin-1 and chemical inhibitors blocked LA-induced autophagy, but did not abrogate LA-triggered MGMT degradation. Concomitant with MGMT depletion, LA pretreatment resulted in enhanced O 6 -methylguanine levels in DNA. It also increased the cytotoxicity of the alkylating anticancer drug temozolomide in temozolomide-resistant colorectal cancer cells. Taken together, our study showed that the natural compound LA inhibits MGMT and induces autophagy. Furthermore, LA enhanced the cytotoxic effects of temozolomide, which makes it a candidate for a supplement in cancer therapy.
Introduction
The DNA repair protein O 6 -methylguanine-DNA methyltransferase (MGMT) removes the cytotoxic and premutagenic DNA adduct O
6
-methylguanine (O 6 -MeG), which is induced by S N 1-alkylating agents such as N-nitroso compounds found in food and tobacco-smoke (1) . Thereby, MGMT represents an important barrier against alkylation-induced carcinogenesis (2) . Furthermore, S N 1-alkylating agents are also applied in cancer chemotherapy, where MGMT is a resistance factor that limits therapeutic efficacy (3) . MGMT catalyzes the transfer of the methyl group from O 6 -MeG onto a cysteine residue located in its catalytic cleft, which results in the restoration of guanine in DNA. This covalent modification causes an irreversible inactivation of MGMT, followed by its fast proteasomal degradation (4, 5) . MGMT expression and activity are regulated by diverse mechanisms. First, MGMT gene expression is under the control of several transcription factors, such as nuclear factor-kappaB (NF-κB) and SP-1, and is directly linked to its promoter methylation, with hypermethylation leading to its downregulation and loss of activity (6) . Second, MGMT protein level is regulated by post-translational modification with ubiquitin moieties following methyl group transfer (5) . The covalent modification is thought to induce a conformational change, thereby marking MGMT as substrate for cellular E3 ubiquitin-ligases (7) . Third, MGMT activity is modulated by pharmacological inhibitors, such as the pseudosubstrate O 6 -benzylguanine, and also by natural compounds. It was reported that the coffee diterpenes kahweol and cafestol increase the hepatic MGMT activity in a dose-dependent manner (8) . Another study showed that thiolcontaining compounds like N-acetyl cysteine (NAC) and natural antioxidants including curcumin raise the MGMT protein level and its activity in colorectal cancer (CRC) cells (9) . In contrast, the dithiol-containing drug disulfiram was described as potent MGMT inhibitor that promotes its proteasomal degradation (10) .
α-Lipoic acid (LA) is a disulfide-containing substance, which acts as an essential cofactor of the mitochondrial pyruvate dehydrogenase enzyme complex (11) . This natural compound is not only endogenously synthesized, but also absorbed in the gastro-intestinal tract following oral supplementation. After transporter-mediated internalization, LA undergoes nicotinamide adenine dinucleotide phosphate-dependent conversion into its reduced form dihydrolipoic acid (DHLA), forming a potent redox couple (12, 13) . Both LA and DHLA show numerous antioxidative properties, including the elimination of reactive oxygen species, regeneration of vitamin C and an increase in glutathione (GSH) levels (14) . The latter is attributable to an enhanced formation of cysteine from its oxidized form cystine and to an LA-mediated activation of the redox-sensitive transcription factor Nrf2 (15, 16) . Owing to these functions, LA exhibits therapeutic potential for the treatment of diabetic polyneuropathy, a chronic disease characterized by high ROS production (17) . In addition, LA possesses anti-inflammatory properties by inhibiting NF-κB activity and has been shown to reduce inflammation in vivo (18, 19) . Interestingly, LA has also been demonstrated to suppress the growth of tumour cells and to induce cell death, which was associated with a modulation of the cellular redox state (20) (21) (22) . This is supported by our own data showing that LA induces cell death in CRC cells in a p53-independent manner (23) . Interestingly, HCT116 cells displayed a considerably lower sensitivity to LA as other CRC cell lines tested, which points to survival mechanisms triggered by LA. In this context, it is important to note that a novel LA derivative was reported to induce autophagy in the CRC cell line HT29 (24) . Autophagy is a lysosomal degradation pathway triggered by nutrient deprivation and oxidative stress (25) . This process is essential for the maintenance of cell homeostasis and has recently been linked to the regulation of DNA repair proteins (26, 27) .
Given that LA modulates the cellular thiol pool and exhibits a highly reactive dithiolane ring, we set out to determine its effect on MGMT in vitro and in cultured cells. First, the influence of LA on MGMT activity was assessed using both recombinant and cellular MGMT, showing pronounced inhibition of its activity. We also investigated LA-mediated changes in MGMT gene expression and protein levels, revealing MGMT protein depletion. Subsequently, putative LA-dependent autophagy induction was analyzed in CRC cell lines with respect to their p53 status and MGMT degradation, including the use of pharmacological inhibitors and genetic approaches to modulate autophagy. Finally, we analyzed the cellular consequences of LA-induced MGMT depletion in response to temozolomide, a S N 1-alkylating anticancer drug, showing increased O 6 -MeG DNA adduct levels and enhanced cell death induction.
Material and methods

Cell lines and culture conditions
The two isogenic colorectal carcinoma (CRC) cell lines HCT116-p53 +/+ and HCT116-p53 −/− were from Prof. Dr Bert Vogelstein (John Hopkins University, Baltimore) and were obtained from the Core Cell Center (John Hopkins University) in 2012. Cells were re-authenticated by p53 immunoblotting following ionizing radiation (see Supplementary Figure 1 , available at Carcinogenesis Online) and by their characteristic differential response to 5-FU (28) as tested 4 month ago. The CRC cell line CaCO-2 was received from Dr Cornelia Dietrich (Department of Toxicology, University Medical Center Mainz, Germany) in 2012. CaCO-2 cells bear mutant p53 that is almost undetectable on protein level (29) . CaCO-2 cells were re-authenticated by their p53 status and typical enterocytelike morphology, which was assessed regularly by light microscopy. The CRC cell line RKO was provided Prof. Dr Oliver H. Krämer in 2014 and re-authenticated by their wild-type p53 status and their morphology. HCT116 and RKO cells were grown in Dulbecco's modified Eagle's medium containing 10% fetal calf serum, 100 U/ml penicillin and 100 µg/ ml streptomycin. CaCO-2 cells were maintained in modified Eagle's medium with 10% fetal calf serum, antibiotics and 1% non-essential amino acids. All cells were cultured at 37°C in humidified atmosphere of 5% CO 2 and 95% air. Cell culture medium and supplements were obtained from Gibco Life Technologies (Darmstadt, Germany) unless otherwise stated.
Drugs and drug treatment
A 200 mM R (+) LA (Sigma, Munich, Germany) stock solution was prepared in 100% ethanol. LA was directly added to cells in fresh medium and incubated for the time periods indicated. As control, ethanol was used corresponding to the respective LA dose. DHLA (Sigma, Munich, Germany) was diluted in 100% ethanol to obtain a 200 mM stock solution. TMZ (Schering-Plough, Kenilworth, IL) was prepared and used as described previously (30) . The autophagy inhibitors bafilomycin A1 and chloroquine (CQ) were obtained from Sigma. For inhibition of the autophagic flux, cells were treated with 10 nM bafilomycin A1 for 6 h before harvesting, CQ (20 µM) was added 30 h after LA treatment for 18 h. Due to the ineffectiveness of rapamycin as autophagy inducer in HCT116 cells 10 µM oxaliplatin (Hospira, Munich, Germany) were used. Standard chemicals were purchased at Sigma unless otherwise stated. 
Abbreviations
Antibodies used for western blot analysis
Antibody against Rad51 was from Abcam (Cambridge, UK) and antibodies against Akt, p-Akt, beclin-1 and LC3B were from Cell Signaling (Denver, CO). The antibodies against ß-actin, Hsp90, p62/ SQSTM1, proliferating cell nuclear antigen, NF-κB and p53 were obtained from Santa Cruz Biotechnology (Heidelberg, Germany). Poly (adenosine diphosphate ribose) polymerase-1 antibody (PARP-1; clone CII10) was a kind gift of Prof. Dr Alexander Bürkle (University of Konstanz, Germany). Streptavidinperoxidase was purchased from Roche (Mannheim, Germany) and MGMT antibody was from Merck Millipore (Billerica, USA). All antibodies were tested for specificity and have been used previously in numerous studies (23, (31) (32) (33) (34) (35) .
Transient transfection with siRNA against beclin-1
Small interfering RNA (siRNA) knockdown of beclin-1 was performed using siGENOME SMARTpool siRNA purchased from Thermo Scientific (Waltham, MA). At 40% confluency cells were transfected with 20 nM siRNA using Lipofectamine® RNAimax (Invitrogen, Darmstadt, Germany). Non-sense siRNA was used as negative control. About, 24 h following transfection cells were treated with 1000 µM LA and harvested after 48 h. Beclin-1 knockdown was verified by western blot analysis.
Analysis of cell death by flow cytometry and cell viability assay
Cell death frequency was assessed by Annexin-V/PI staining as described previously (36 
Determination of reduced and oxidized GSH
Total glutathione (GSH + glutathione disulfide [GSSG]), oxidized GSSG and GSH/GSSG ratio were assessed in HCT116 cells using GSH/GSSG-Glo™ Assay (Promega). Cells were seeded in white 96-well plates and treated with increasing doses of LA as indicated. After 24 h, GSH/GSSG-Glo™ Assay was performed according to the manufacturer's instructions using a MicroLumat Plus 96-well plate reader (Berthold).
Analysis of autophagy induction by flow cytometry
Autophagy induction was monitored using Cyto-ID® Autophagy Dectection Kit (Enzo Life Science, Lörrach, Germany). To this end, cells were seeded on 6 cm dishes and treated with increasing LA concentration for 48 h. About 10 µM oxaliplatin was used as positive control. After treatment, both attached and detached cells were harvested, centrifuged and washed with phosphate-buffered saline. Cells were stained according to manufacturer's protocol. Samples were measured by flow cytometry and analyzed using the BD FACSDiva software (BD Biosciences).
Immunofluorescence
HCT116 cells grown on cover slips were treated with 500 and 1000 µM LA for 48 h. Cells were fixed for 10 min in ice-cold methanol at −20°C. The samples were blocked in phosphate-buffered saline containing 5% (w/v) bovine serum albumin and 0.3% (v/v) Triton X-100 for 1 h. Following incubation with primary antibody against LC3B (Cell Signaling, MA) for 1 h, the cells were incubated with a secondary antibody coupled with Alexa Fluor 488 (Life Technologies) for another hour. DNA was then stained with TO-PRO-3 (Life Technologies) for 15 min. Cells were mounted using Vectashield® (Vector Labs, Burlingame, CA) and analyzed by confocal microscopy with a Zeiss Axio Observer.Z1 microscope equipped with a LSM710 laser-scanning unit (Zeiss, Oberkochen, Germany). Images were acquired by ZEN software and further analyzed using ImageJ (NIH, MD).
Preparation of protein extracts
To prepare whole-cell extracts cells were lysed in buffer containing 25 mM Tris-HCl pH 8.0, 5 mM ethylenediaminetetraacetic acid (EDTA), 1 mM dithiothreitol (DTT), 0.5 M NaCl supplemented with cOmplete protease inhibitor cocktail (Roche Diagnostics, Mannheim, Germany), 1 mM Na 3 VO 4 and 2 mM NaF. Nuclear extracts were prepared by resuspending cell pellets in Lysis buffer A (10 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid-KOH pH 7.9, 1.5 mM MgCl 2 , 10 mM HCl, 1mM DTT, 1× protease inhibitor cocktail, 1 mM Na 3 VO 4 , 2 mM NaF) and incubation on ice for 15 min followed by addition of NP-40 to a final concentration of 1% (v/v). Samples were then centrifuged to isolate the supernatant containing the cytoplasmic fraction. The pellet containing nuclei and membranes was lysed in Lysis buffer B (20 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid-KOH pH7.9, 420 mM NaCl, 1.5 mM MgCl 2 , 0.5 mM EDTA, 25% Glycerol, 1× protease inhibitor cocktail, 1 mM Na 3 VO 4 , 2 mM NaF) on ice for 20 min. After centrifugation at 20.000g for 10 min, the nuclear fraction was obtained as supernatant.
Whole-cell extracts for MGMT activity assay were prepared by resuspending cell pellets in buffer containing 20 mM Tris-HCl pH 8.5, 1 mM EDTA, 1 mM β-mercaptoethanol, 5% glycerol and 0.1 mM phenylmethylsulfonyl fluoride. The samples were disrupted on ice by sonication and the lysate was cleared by centrifugation. Protein content of clarified extracts was determined by the Bradford assay.
Western blot analysis
Equal amounts of protein samples were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) followed by transfer to a nitrocellulose membrane (Perkin Elmer, Rodgau, Germany) with a wet-blot chamber (Bio-Rad, München, Germany). About 5% (w/v) non-fat dry milk in tris-buffered saline (TBS) containing Tween-20 [0.1% (v/v), TBS-T] was used to block the membrane for 1 h. The membrane was subsequently probed with primary antibody. After washing the membrane with TBS-T, it was incubated with the appropriate secondary antibody coupled to horseradish peroxidase (Santa Cruz Biotechnology). Subsequently, final washing steps were performed and proteins were detected by chemiluminescence using Western Lightning® Plus-ECL (Perkin Elmer). Densitometric evaluation of blots was performed by Adobe Photoshop CS5 software and analyzed by GraphPad Prism 5 software as indicated.
Expression and purification of MGMT
Human MGMT was expressed as glutathione-S-transferase (GST)-tagged fusion protein in Escherichia coli BL 21 and purified by a protocol described previously (31, 37) . Transformed bacteria were cultivated in rich growth medium (1% (w/v) trypton, 0.5% (w/v) yeast extract, 1% (w/v) NaCl) with 100 µg/ml ampicillin overnight at 37°C. The culture was then used to inoculate 900 ml of the growth medium to an optical density of 0.04. After reaching an optical density of 0.8 isopropyl-ß-D-thiogalactoside was added to a final concentration of 500 µM to induce protein expression. Culture was incubated for a further 5 h at 37°C and harvested by centrifugation at 10.000g for 15 min. Cell pellets were lysed using buffer containing: 10 mM NaCl, 20 mM Tris-HCl pH 7.4, 1% Triton X-100 (v/v), 1 mM phenylmethylsulfonyl fluoride, 1 mM DTT. The cells were disrupted on ice by sonication. Lysate was cleared by centrifugation at 20.000g for 15 min. GST-tagged MGMT was isolated using GSH sepharose 4B beads (Macherey-Nagel, Düren, Germany). The GST-tag was removed by incubation with 20 U thrombin (GE Healthcare, Freiburg, Germany) for 1 h and released MGMT was collected. Eluate was subjected to SDS-PAGE followed by Coomassie staining and western blot analysis.
MGMT activity assay
MGMT activity of recombinant and cellular MGMT was determined using a radioactive assay based on the transfer of 3 H-labeled methyl groups from the O 6 -position of guanine to the MGMT protein.
The assay was performed as previously reported (38) . Extracts of MGMT-deficient HeLa MR cells served as negative control, whereas HeLa S3 cell extracts served as positive control. 150 µg of protein extract obtained from HCT116 cells were used for the assay. Recombinant MGMT was used at a concentration of 27 ng/µl. Each assay was performed in duplicates or triplicates. Radioactivity of the samples was measured by scintillation counting and further analyzed using GraphPad Prism.
To study the effects of LA on MGMT in more detail, we made use of SNAP-Biotin® (New England Biolabs, Frankfurt am Main, Germany), which is a biotin-labeled derivative of the MGMT pseudosubstrate O 6 -benzyl guanine (O 6 -BG). Recombinant MGMT (1 µM) was preincubated for 20 min with increasing doses of LA or 1 mM N-ethylmaleimide, which covalently modifies free thiol groups. Subsequently, the substrate SNAP-Biotin® was added (2.5 µM) and the reaction mixture was further incubated for 30 min at 37°C. Transfer of the biotin-labeled benzyl group onto Cys-145 of MGMT was assessed by SDS-PAGE and western blot detection with streptavidin-peroxidase.
Quantitative reverse transcriptase-PCR
Cells were seeded on 10 cm dishes and treated with different LA concentrations for up to 48 h. Thereafter, cells were harvested and RNA was isolated using Nucleospin® RNA II Kit (Macherey-Nagel). 1 µg RNA was reverse-transcribed using Verso cDNA Synthesis Kit (Thermo Scientific). Complementary DNA synthesis was performed for 60 min at 42°C. The obtained complementary DNA was amplified using the SYBR® GreenER™ qPCR Supermix for iCycler® Kit (Invitrogen) containing a hot-start Taq DNA polymerase. The PCR included one stage of 2 min at 50°C, a denaturation step for 10 min at 95°C followed by 44 cycles of 10 min at 95°C, 20 s at 58°C and 20 s at 72°C. Two steps of 10 s at 95°C and 5 s at 65°C finalized the assay. PCR was performed using Real-Time-Cycler CFX96 C1000 (BioRad, Munich, Germany). All experiments were performed in triplicates. The MGMT gene expression was normalized to actin and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) expression. Data were analyzed using CFX Manager 3.0 software (Bio-Rad) and GraphPad Prism 5.0.
The following primers were used for real-time PCR: MGMT, 5′-CTCTTCACCATCCCGTTT-3′
(forward), 5′-AATCACTTCTCCG AATTTCAC-3′ (reverse); β-actin, 5′-TGGCATCCACGAAACTACC-3′ (forward), 5′-GTGTTGGCGTACAGGTCTT-3′ (reverse); glyceraldehyde 3-phosphate dehydrogenase, 5′-CATGAG-AAGTATGACAACAG-3′ (forward), 5′-ATGAGTCC TTCCACGATA-3′ (reverse).
Detection of O 6 -methylguanine DNA adducts
First, antibody specificity and sensitivity was tested using calf thymus DNA (CT-DNA) that was treated or not with 500 µM N-methyl-Nnitrosourea (MNU), which is a S N 1-alkylating agent generating O 6 -MeG adducts (39) . In brief, CT-DNA was reacted with 500 µM MNU for 2 h at 37°C followed by 2 h at 25°C. The reaction was then cooled on ice, supplemented with 0.25 M sodium acetate and precipitated with ethanol at −20°C. CT-DNA was pelleted by centrifugation at 6.000g and washed with ethanol. Finally, the pelleted DNA was air-dried and dissolved in TE buffer. Purity and concentration were determined by UV absorbance using a NanoDrop 2000 (Thermo Scientific, Dreieich, Germany) and DNA was stored at −80°C. Next, a dose-response curve of O 6 -MeG adducts was established in HCT116 cells using increasing doses of TMZ (0-1000 µM). Cells were pretreated with 10 µM O 6 -BG to deplete cellular MGMT activity and then incubated with TMZ for 2 h. Cells were harvested, lysed and subjected to ribonuclease A digestion followed by proteinase K incubation overnight. Genomic DNA was isolated by phenol-chloroform extraction, precipitated by 70% ice-cold ethanol and finally dissolved in TE buffer pH 7.4. DNA concentration and purity were determined as described for CT-DNA. To study the impact of LA on MGMT depletion and TMZ-induced O 6 -MeG levels, cells were pretreated with 1000 µM LA for 48 h or left untreated. Following medium exchange, cells were incubated in the absence or presence of 500 µM TMZ for 2 h. Cells were harvested and genomic DNA was prepared as mentioned above.
To determine O 6 -MeG adduct levels, a slot blot assay was used. First, sample DNA was denatured by heating for 10 min at 99°C followed by the addition of 2 M ammonium acetate. 500 ng of DNA were immediately vacuum-aspirated onto a positively charged nylon membrane (GE Healthcare, Munich, Germany) using a slot-blot manifold. Subsequently, the membrane was fixed for 90 min at 90 °C and blocked with 5% (w/v) non-fat dry milk in TBS-T. O 6 -MeG was visualized with a monoclonal antibody (Axxora, Farmingdale, NY) followed by a secondary peroxidase-coupled antibody and enhanced chemoluminescence detection. Densitometric evaluation of blots was performed by Adobe Photoshop CS5 software and analyzed by GraphPad Prism 5 software.
Animal studies
Sex-matched Balb/c nu/nu mice, 8-10 weeks old, were housed in a sterile environment and allowed free access to food and water. Animal experiments were approved by the government of Rhineland-Palatinate and the Animal Care and Use Committee of the University Medical Center Mainz and performed in accordance with the guidelines for the protection of animals. To initiate HCT116 xenografts, 5 × 10 6 cells were inoculated subcutaneously into the right and left flank of each mouse. After tumour volumes reached a suitable size, at least five animals each were assigned to the different groups (control, LA, TMZ, LA + TMZ) and tumour volume was standardized across the groups. As pretreatment, mice received once daily an intraperitoneal injection of LA (50 mg/kg body weight; dissolved in ethanol and diluted with physiological saline) over 6 days. Subsequently, one dose of TMZ (150 mg/ kg bw; dissolved in dimethyl sulfoxide and diluted with physiological saline) was administered intraperitoneal and LA injections were continued every second day as outlined in Figure 6D . Control animals received the solvent controls in physiological saline. Tumour volumes were determined as indicated.
Statistical analysis
All in vitro and cell culture experiments were performed independently at least twice. Results from representative experiments are shown. Values are presented as means ± standard errors of the means (SEM) using GraphPad Prism 5.0 Software. Statistical significance was determined using Student's t-test.
Results
LA inhibits MGMT in vitro and in CRC cells
We first assessed whether or not the disulfide compound LA affects MGMT activity in vitro. To this end, recombinant human MGMT was overexpressed as GST-tagged fusion protein and purified to homogeneity. The GST-tag was removed by thrombin cleavage, yielding native MGMT with high purity as revealed by Coomassie staining ( Figure 1A) . To assess the effect of LA on MGMT, increasing concentrations of LA were incubated with MGMT and its activity was measured, revealing a dose-dependent reduction with 75% inhibition at 50 µM LA ( Figure 1B ). Based on these results, an IC 50 value of 29.5 µM was calculated (Supplementary Figure 2A , available at Carcinogenesis Online). Moreover, DHLA was tested with regard to its MGMT inhibitory potential. In contrast to LA, its reduced form caused only a slight decrease in MGMT activity at high doses ( Figure 1B ). Given that LA bears a reactive disulfide group, we speculated that LA may interfere with or modify the essential thiol group of Cys-145 located in the catalytic center of MGMT, thereby abolishing its activity. In order to attenuate the inhibitory effect of LA, we preincubated MGMT with the thiol-containing antioxidant NAC followed by supplementation with 40 µM LA, which on its own decreased MGMT activity to 38% compared with untreated MGMT. Interestingly, NAC pretreatment up to 10 mM partially restored MGMT activity to about 60% of the control ( Figure 1C ). To analyze the inhibitory effect of LA in more detail, we made use of biotin-labeled O MGMT ( Figure 1D ). Importantly, pretreatment with LA resulted in a dose-dependent decrease of biotin-labeled MGMT, similar to that observed with the thiol-reactive probe N-ethylmaleimide used as positive control. This experiment strongly suggests that LA pretreatment results in chemical modification of the critical Cys-145 residue, which is therefore not available as acceptor site for the biotin-conjugated benzyl group. The inhibitory effect of LA was not reverted by addition of DTT as evidenced by the MGMT alkyltransferase assay with Biotin-O 6 -BG (Supplementary Figure 2B , available at Carcinogenesis Online).
Subsequently, the inhibitory effect of LA on MGMT activity was tested in HCT116 CRC cells, which were used previously to study the influence of cysteine prodrugs and antioxidants on MGMT (9). Cells were incubated with 100 and 1000 µM LA for 24 and 48 h, respectively, and MGMT activity was determined. A dose of 100 µM LA moderately reduced MGMT activity after 24 h, but hardly affected its activity after 48 h ( Figure 1E ). In contrast, treatment with 1000 µM LA led to a pronounced decrease in MGMT activity by ~35% already after 24 h, with a further reduction by 55% after 48 h compared with control cells. Taken together, the disulfide compound LA was identified as a novel direct inhibitor of MGMT in vitro and also suppressed MGMT activity in cultured tumour cells.
LA induces the depletion of MGMT on protein level
We then determined whether the observed LA-dependent inhibition of MGMT in HCT116 cells is related to changes in MGMT protein or messenger RNA level. To this end, cells were treated with increasing doses of LA (100, 500 and 1000 µM) for 48 h followed by cell fractionation in order to analyze the subcellular localization and quantity of MGMT. The nuclear DNA repair protein PARP-1 and the cytoplasmic chaperone Hsp90 were used as loading controls and to monitor efficient separation. 100 µM did not affect MGMT protein level, whereas 500 µM already caused a reduction of the nuclear MGMT pool (Figure 2A) . A striking depletion in nuclear and cytoplasmic MGMT was observed following 1000 µM LA, which is in line with the MGMT activity data shown before. Interestingly, LA treatment did not affect the redox-responsive transcription factor NF-kB (Supplementary Figure 3A, available at Carcinogenesis Online). Depletion of MGMT in response to LA treatment was not only observed in whole cell extracts from HCT116 cells, but also confirmed in RKO cells ( Figure 2B ). Subsequently, the long-term effects of low LA doses on MGMT level were studied. Cells were incubated over 144 h with 50 up to 200 µM LA and MGMT was assessed in whole cell lysates, showing a dose-dependent decrease of MGMT ( Figure 2C ). LA also downregulated Rad51 protein, which is involved in homologous recombination-mediated repair (Supplementary Figure 3B and C, available at Carcinogenesis Online), indicating that LA may also impact the level (and activity) of other cellular proteins. Densitometry of western blots revealed a reduction of MGMT by 35% at 100 µM LA, whereas 200 µM induced a reduction by 55% compared with control cells ( Figure 2D ). In order to analyze an impact of LA on MGMT gene expression, cells were treated for 24 or 48 h with 100 and 1000 µM LA and RNA was isolated. Quantitative reverse transcriptase-PCR was performed to determine MGMT expression levels in relation to the housekeeper genes GAPDH and ß-actin. Incubation with LA had no influence on the relative MGMT level ( Figure 2E and Supplementary Figure 2C , available at Carcinogenesis Online), arguing against a 
LA-induced loss of MGMT is not reverted by NAC and LA treatment modulates the cellular GSH pool
To address the role of other thiol-containing compounds, HCT116 cells were incubated with increasing doses of the antioxidant NAC for 48 h. In stark contrast to LA, NAC treatment did not reduce the MGMT protein level, but rather increased the nuclear MGMT content ( Figure 2F ). Next, we wondered whether pretreatment of cells with NAC is able to rescue LA-triggered depletion of MGMT. To this end, cells were pretreated with NAC for 48 h and then challenged with LA for another 48 h. Western blot analysis revealed no protective effect of NAC towards LA, but rather slightly enhanced degradation of MGMT by LA (Supplementary Figure 3D , available at Carcinogenesis Online). NAC on its own also negatively affected the MGMT level compared with control cells, which is possibly a result of the long-term incubation. This is supported by the fact that nuclear PARP-1 also disappeared in the NAC containing samples. Therefore, proliferating cell nuclear antigen was included as additional loading control.
LA is known to modulate the cellular thiol pool, particularly by increasing reduced GSH via distinct mechanisms (14) . Hence, the levels of reduced GSH, oxidized GSSG and total GSH (GSH + GSSG) were determined 24 h after treatment with increasing concentrations of LA. Both total GSH and reduced GSH were elevated in a dose-dependent manner by LA ( Figure 3G and H). LA also increased cellular GSSG levels up to a dose 500 µM, whereas treatment with 1000 µM LA resulted in a decrease of GSSG to control levels ( Figure 3I ). The GSH/GSSG ratio was remained unchanged up to 500 µM LA, with an increase at 1000 µM (Table 1) .
Taken together, the thiol-containing antioxidant NAC caused a moderate increase of MGMT protein in CRC cells, but did not rescue LA-triggered depletion of MGMT. Furthermore, LA treatment dose-dependently improved both reduced and total GSH pools with an elevated GSH/GSSG ratio at the highest dose.
LA induces autophagy in HCT116 cells
A previous study indicated that a synthetic LA derivative is capable of inducing autophagy (24), a cellular process that has been recently associated with the regulation of some DNA repair proteins (26, 27) . This let us to speculate that LA might trigger MGMT degradation via autophagy. To test this hypothesis, HCT116 cells were treated with increasing doses of LA for 48 h and autophagosome formation was monitored by flow cytometry using Cyto-ID® staining. A strong, dose-dependent increase of autophagosome fluorescence was observed following LA treatment, reaching a 3-fold induction at 1000 µM LA compared with control cells ( Figure 3A) . The LA-dependent upregulation of autophagy was already visible after 24 h, albeit to a lower extent (Supplementary Figure 4A , available at Carcinogenesis Online). To analyze this finding in more detail, we monitored LC3B levels as important autophagy marker. LC3B is converted during autophagy from LC3B-I to LC3B-II, which is present in autophagosomes and correlates with their number. Treatment of cells with LA for 48 h led to a pronounced increase of LC3B-II levels, with a maximum at 500 µM LA as revealed by western blot analysis ( Figure 3B ). In addition, the autophagy receptor p62 was studied, which interacts with LC3B and recognizes misfolded/ aggregated proteins to promote their degradation by autophagy (40) . Interestingly, p62 was induced in a dose-dependent manner by LA, coincident with the increase in LC3B-II ( Figure 3B ). Both proteins were reduced at the highest LA dose, which may point to an advanced stage of autophagy linked to p62 and LC3B degradation. It should be noted that LC3B conversion was not observed after 24 h, whereas a modest increase in p62 levels was detected (Supplementary Figure 4B , available at Carcinogenesis Online). As MGMT depletion has also been detected in RKO cells ( Figure 2B ), LA-dependent autophagy induction was tested in this cell line as well. LA-stimulated autophagy in RKO cells as evidenced by a strong increase in LC3B-II levels that peaked at 500 µM LA ( Figure 3B ). Furthermore, p62 was induced in a LA-dependent manner and autophagosome formation was enhanced 48 h after LA incubation (Supplementary Figure 4C , available at Carcinogenesis Online). We then analyzed the LA-dependent formation of LC3B-positive autophagic vesicles by confocal microscopy, showing a significant increase in LC3B-positive cells after LA treatment for 48 h (Figure 3C and D) . To better characterize LA-dependent autophagy induction, the phosphorylation status of protein kinase B/Akt was assessed. Inactivation of Akt by dephosphorylation is known to suppress mammalian target of rapamycin (mTOR) activity, leading to the induction of autophagy (41) . Interestingly, HCT116 cells treated with LA for 48 h displayed a pronounced dephosphorylation of Akt, which was accompanied by the induction of the autophagy marker LC3B-II ( Figure 3E ). In order to compare LA to other thiol-containing antioxidants, a similar set of experiments was repeated using NAC. In contrast to LA, treatment with increasing doses of NAC (0.5 up to 5 mM) did not result in enhanced LC3B-II levels ( Figure 3F ). Likewise, no increased formation of autophagosome was observed by Cyto-ID staining, supporting the lack of autophagy induction by NAC ( Figure 3G ). In conclusion, our findings showed a time-and dose-dependent induction of autophagy by LA in HCT116 and RKO cells, whereas the antioxidant NAC had no influence on basal autophagy.
LA triggers autophagy in a p53-independent manner
We then addressed the role of the tumour suppressor p53 in LA-induced autophagy. Besides its role in cell cycle and apoptosis, p53 is also critically involved in the regulation of cell metabolism and autophagy (42) . To this end, we used isogenic p53-null HCT116 cells (Supplementary Figure 1 , available at Carcinogenesis Online), which were incubated with increasing LA doses for 48 h and then subjected to Cyto-ID® staining. Interestingly, LA promoted autophagosome formation to the same level as observed in p53-proficient HCT116 cells ( Figure 4A ). Likewise, LA increased LC3B-II levels in HCT116-p53 −/− cells similar to the effect shown in corresponding HCT116-p53 +/+ cells, supporting the notion that LA induces autophagy in a p53-independent manner ( Figure 4B) . In addition, we tested p53-mutated CaCO-2 as another CRC cell line and analyzed LA-dependent autophagosome formation as well as LC3B conversion. However, no increase in autophagosome fluorescence was found in CaCO-2 cells 48 h after LA incubation, whereas the anticancer drug oxaliplatin significantly enhanced autophagosome staining (Supplementary Figure 5C , available at Carcinogenesis Online). In agreement with these results, LA treatment did not increase LC3B-II levels, but rather reduced LC3B-I and II at high doses. In contrast, oxaliplatin led to a moderate increase in LC3B-I and II levels (Supplementary Figure 5D , available at Carcinogenesis Online). No effects were seen after 24 h of LA incubation (Supplementary Figure 5A and B, available at Carcinogenesis Online). Altogether, we provide evidence that LA triggers autophagy in a rather cell-type specific manner, which does not require the presence of wild-type p53.
Inhibition of LA-dependent autophagy does not rescue concomitant MGMT depletion
Subsequently, we made use of pharmacological inhibitors and genetic approaches to modulate LA-dependent autophagy in p53-proficient HCT116 cells and studied their impact on MGMT. Defects in the late stages of autophagy can inhibit LC3B-II degradation, thereby also leading to an accumulation of LC3B-II (43) . In order to analyze this issue in more detail, cells were treated with LA up to 48 h and supplemented with bafilomycin A1 (Baf A1) for 6 h before cells were harvested. Baf A1 inhibits the acidification of endosomal and lysosomal vesicles, which subsequently blocks the formation of autolysosomes. Cells that were incubated with the inhibitor displayed a strong accumulation of LC3B-II as expected ( Figure 4C and Supplementary Figure 6A , available at Carcinogenesis Online). LA dose-dependently increased LC3B-II levels compared with control cells both in the absence and the presence of Baf A1, indicating that LA promotes the autophagic flux, i.e. the whole process of autophagy ( Figure 4C ). In addition, cell death induction was determined by Annexin-V/PI staining and revealed a Figure 6B , available at Carcinogenesis Online). We also tested the influence of CQ on LA-induced autophagy. CQ suppresses the acidification of lysosomes and thereby inhibits the late stages of autophagy. To this end, cells were incubated with LA and CQ was added after 30 h. After a total incubation period of 48 h, cells were harvested and autophagosome formation was analyzed using CytoID®-staining. The combination regime caused an almost 3-fold induction of autophagosome fluorescence compared with the single treatment with LA or CQ ( Figure 4D) , indicating an accumulation of autophagosomes due to a blockage of autophagosomal-lysosomal fusion. In agreement with this finding, CQ also dramatically increased LC3B-II levels in concert with LA, supporting the notion that LA activates the whole process of autophagy ( Figure 4E ). At the same time, we monitored the LA-mediated changes in MGMT in response to the different treatments. As observed before, LA triggered a dose-dependent depletion of MGMT protein.
Supplementation with the autophagy inhibitor CQ did not block the LA-dependent decrease in MGMT, but rather seems to increase the MGMT degradation. Interestingly, this effect was also observed in untreated control samples, in which CQ had been added ( Figure 4E ). 18 h before harvesting CQ was added. Samples were subjected to SDS-PAGE followed by detection with antibody against MGMT and LC3B. Hsp90 was used as loading control. (F) HCT116 cells were transiently transfected with scrambled (Scr) or beclin-1-specific siRNA. 24 h after transfection, cells were treated with 1000 µM LA for 48 h. Whole-cell extracts were analyzed by immunoblot using antibodies against MGMT and LC3B. Hsp90 served as loading control, whereas Beclin 1 was visualized to confirm efficient knockdown. Representative blots are shown.
To further address the link between autophagy induction and MGMT depletion, we performed a siRNA-mediated knockdown of beclin-1. This protein is part of the Vps34 complex, which is of fundamental importance for the induction of autophagy owing to its class III PI3-Kinase activity (44) . Knockdown efficiency was assessed by western blot analysis and revealed a strong siRNAmediated reduction of beclin-1 already after 24 h (Supplementary Figure 6C , available at Carcinogenesis Online). Beclin-1 levels were almost undetectable between 48 and 72 h following transfection. Thus, cells were treated with LA 24 h following transfection, incubated for another 48 h and subjected to LC3B immunodetection. LA induced an accumulation of LC3B as described above, which was almost unaffected in cells transfected with scrambled siRNA ( Figure 4F) . Importantly, knockdown of beclin-1 strongly attenuated LA-dependent LC3B-II induction, demonstrating the contribution of beclin-1 to LA-triggered autophagy. MGMT was also detected, revealing almost no effect of beclin-1 abrogation on MGMT protein levels, which suggests that autophagy is not responsible for or contributes only little to the observed concomitant MGMT degradation ( Figure 4F ). In summary, these findings demonstrate the LA promotes the autophagic flux in HCT116 cells in a beclin-1 dependent manner, which is not required for MGMT depletion.
LA enhances alkylating agent-induced O 6 -MeG levels and cytotoxicity
We were further interested whether LA-induced reduction in MGMT levels will affect the cellular response to S N 1-alkylating agents. First, we established an immunological slot blot method to determine O 6 -MeG adducts, the substrate of MGMT. To illustrate the specificity and sensitivity of the used O Figure 5A ). This was confirmed in several independent experiments and quantified by densitometry, demonstrating a significant dose-dependent increase in adduct levels ( Figure 5B -MeG levels, yielding a significant increase of about 50% compared with TMZ single treatment ( Figure 5C and, for quantification, Figure 5D ).
Having shown the increased formation of O 6 -MeG, the cytotoxic effects of LA pretreatment (48 h) together with TMZ administration and further incubation for 96 h were studied by Annexin-V/PI staining and flow cytometry ( Figure 6A and B) . Incubation with 200 µM LA on its own elevated the cell death rate by 10% compared with control cells, whereas single treatment with 500 µM TMZ increased the cell death rate by 20% ( Figure 6A ). The combination treatment further potentiated cell death induction by 30% as related to control cells, which suggests an additive rather than a sensitizing effect provoked by LA. As additional endpoint, cell viability was determined using the adenosine triphosphate (ATP) assay. LA single treatment slightly decreased viability in HCT116 cells, whereas cells challenged with TMZ displayed a reduction by 30% ( Figure 6C ). The combination regime with LA and TMZ suppressed viability by 60% compared with control cells (Figure 6C ), confirming the findings obtained by Annexin-V/PI staining. A same set of experiments was conducted in RKO cells, showing virtually no effect of TMZ and a substantial increased cytotoxicity by addition of LA (Supplementary Figure 7B , available at Carcinogenesis Online).
Finally, we tested the effectiveness of LA as a supplement for tumour therapy using a HCT116 xenograft model, which is known to be resistant to TMZ treatment (45) . HCT116 cells were inoculated in immuno-compromised Balb/c nu/nu mice and tumour-bearing animals were randomized into four treatment groups (control, LA, TMZand LA + TMZ) followed by a treatment schedule as indicated ( Figure 6D ). Single administration of TMZ resulted in an increased tumour volume by 50% compared with solvent treated control animals after 24 days ( Figure 6E ). This highlights the resistance of this xenograft model to TMZ and indicates an even accelerated tumour growth following the dose of TMZ used. The combination treatment with TMZ and LA substantially reduced the mean tumour volume compared with the group of TMZ-treated animals ( Figure 6E ). Interestingly, administration of LA on its own caused a further moderate delay in tumour growth first detectable on day 18, yielding the smallest tumour volume of all treatment groups (10% reduction versus control animals and 60% reduction versus TMZ group) at the end of the experiment. In conclusion, LA increased the level of toxic TMZ-induced O 6 -MeG DNA adducts. It also enhanced the cytotoxicity in TMZ-resistant cells and moderately retarded tumour growth, compared with the TMZ group, in a TMZ-resistant xenograft model.
Discussion
In the present study, we set out to characterize the effects of the disulfide-containing natural compound LA on MGMT in vitro and in CRC cells. First, we show that LA inhibits the activity of MGMT in vitro with an IC 50 -value of 29.5 µM. This is in the range reported for disulfiram, which reduced the activity of recombinant MGMT by 40% at a dose of 25 µM (10). NO-donors such as S-nitrosoglutathione were also shown to inhibit MGMT in vitro with an IC 50 of 800 µM (46) . The pharmacological MGMT inhibitor O 6 -benzylguanine (O 6 -BG) exhibits an IC 50 of 180 nM (47), which is much lower than that determined for LA. However, one should bear in mind that O 6 -BG is a soluble pseudosubstrate for MGMT, which is even faster repaired than O 6 -MeG adducts in the DNA (48) .
The observed loss of MGMT activity may be attributable to covalent modification of the Cys-145 residue by LA, leading to the formation of mixed lipoyl disulfides. This was analyzed by a MGMT alkyltransferase assay using biotin-labeled O 6 -BG as substrate. Pretreatment of MGMT with LA suppressed the transfer of the biotin-labeled benzyl moiety on MGMT in a dose-dependent manner, strongly suggesting a covalent modification of Cys-145 by LA. A comparable mechanism was described for the related compound disulfiram that attacks and covalently modifies Cys-145 in MGMT (10) . Similarly, S-nitrosoglutathione promotes the formation of S-nitrosocysteine at Cys-145 (46) . Consistent with this model, it was speculated that LA inactivates Keap-1 by covalent modification of its redox-sensitive thiol groups, thereby activating the transcription factor Nrf-2 (11) . In contrast to LA, its reduced form DHLA did not substantially impair MGMT activity, indicating that the highly reactive dithiolane ring of LA is required for the inhibitory effect. LA-dependent reduction of MGMT activity was only partially rescued by the addition of the thiol-containing antioxidant NAC. This may be explained by the insufficient redox potential of NAC or, more likely, by the higher reactivity of Cys-145 in MGMT, which is activated by complex hydrogen bonding interactions in the catalytic cleft, thereby converting it into a highly reactive thiolate anion (49) . Thus, the Cys-145 moiety of MGMT likely represents a preferred substrate for LA.
Subsequently, we analyzed the effects of LA on MGMT in vivo and observed a dose-dependent inhibition of MGMT activity in HCT116 CRC cells, which went along with MGMT protein degradation. Although MGMT activity was potently reduced over 48 h at a dose of 1000 µM LA, it recovered to control levels if cells were treated with 100 µM LA. This may be explained by only partial MGMT inactivation at lower doses and subsequent efficient re-synthesis of MGMT. The depletion of MGMT protein occurred in a dose-dependent manner, starting at a dose of 50 µM LA if cells were chronically exposed for 6 d. LA-induced MGMT depletion was not restricted to HCT116 cells, but also observed in RKO cells. LA did not affect the protein levels of the redox-responsive transcription factor NF-kB, which was reported previously to undergo disulfiram-mediated degradation (50) . Moreover, LA treatment caused a dose-dependent reduction of Rad51 (see Supplementary Data, available at Carcinogenesis Online). We therefore cannot exclude that LA modifies additional cellular proteins bearing activated thiol groups, which has to be addressed in future studies. LA-induced MGMT depletion was delayed and not as strong as observed for disulfiram (10) , which may result from differences in cell uptake, metabolism and/or chemical reactivity. Further experiments revealed that the thiolcontaining antioxidant NAC elevates MGMT levels, but was not able to rescue LA-induced MGMT degradation. We also analyzed LA-elicited changes of the cellular thiol pool, in particular GSH and its oxidized form GSSG. In line with other studies (15, 51) , LA was demonstrated to increase total and reduced GSH levels in a dose-dependent manner and to enhance the GSH/GSSG ratio at high doses. These alterations of the GSH pool may contribute to the inhibition of cellular MGMT activity through protein glutathionylation as reported for p53 and NF-κB in disulfiram-treated tumour cells (50) .
LA is present in the diet, particularly in animal tissues such as muscle and heart as well as in vegetables, albeit in significantly lower amounts (52) . The dietary uptake from these natural sources is yet considered to be insufficient, not providing substantial amounts of LA in the bloodstream (11) . Commercially available dietary oral supplements typically contain between 50 and 600 mg LA and result in plasma concentrations in low µM range, which are unlikely to affect MGMT levels. High LA plasma levels of up to 400 µM may only be reached during therapeutic intervention with high oral or intravenous administration (23, 53) . In this therapeutic setting, LA could predispose cells and tissues to alkylating agents as a consequence of MGMT inactivation. This warrants further studies in patients receiving high doses of LA over a longer period, such as patients with diabetic neuropathy (17) . We excluded LA-mediated effects on MGMT gene expression, suggesting a post-translational mechanism involved in MGMT protein degradation. It is known that covalently modified and, thus, inactivated MGMT undergoes ubiquitination followed by its proteasomal degradation. This pathway has been described in response to treatment with S N 1-alkylating agents or pharmacological inhibitors including O 6 -BG (5), but also after treatment with drugs such as disulfiram and tamoxifen (10, 54) . Interestingly, oxidatively damaged proteins can also be subjected to ubiquitin-independent degradation by the 20s proteasome (55) , which may have contributed to the LA-dependent MGMT degradation.
As autophagy has been recently linked to the degradation of the DNA repair proteins OGG1 and MSH4 (26, 27) , we speculated that LA may stimulate autophagy in CRC cells thus degrading MGMT and contributing to the killing effects observed. Our findings demonstrate that LA induces autophagy in HCT116 and RKO cells as attested by increased formation of autophagosomes and enhanced conversion of LC3B-I to its isoform LC3B-II. Previously, the synthetic LA derivative DHL-TauZnNaLA was reported to upregulate autophagy in HT29 CRC cells (24) . We also showed that, in contrast to LA, the thiol-containing antioxidant NAC did not affect basal autophagy levels. This is in line with a previous study dealing with NAC and GSH, which suppressed both basal and induced autophagy (56) . Interestingly, LA treatment did not enhance basal autophagy levels in p53-mutated CaCO-2 cells, pointing to a cell-type specific mode of action. The observed differences in LA-dependent autophagy induction may be explained by varying expression levels of monocarboxylate transporter, which is important for its cell uptake (13) , divergent intracellular metabolism such as conversion into DHLA (57) and/or celltype specific features of the autophagy machinery. It should be also noted that LA exerts significantly enhanced cytotoxicity in CaCO-2 cells (IC 50 0.5 mM) compared with HCT116 cells (IC 50 1.5 mM) as determined 72 h after treatment (23) . If LA-dependent autophagy was blocked by the chemical inhibitor Baf A1, HCT116 cells displayed enhanced cell death rates after 48 h, indicating that autophagy induction has a cytoprotective function in response to LA treatment. This is consistent with the notion that autophagy promotes cell survival, e.g. under conditions of nutrient deprivation or oxidative stress (58) . Further experiments in HCT116 p53-proficient and -deficient isogenic cells provided evidence that p53 is dispensable for LA-triggered autophagy. The complete signaling pathway responsible for autophagy induction by LA in HCT116 cells remains to be elucidated. The serine/ threonine kinase mTOR is an important negative regulator of autophagy that is under the control of both protein kinase B/ Akt and adenosine monophosphate-activated protein kinase (AMPK). Activation of AMPK is known to block mTOR-mediated signaling and may thereby upregulate autophagy, whereas its inhibition by pharmacological means was reported to suppress autophagy. An earlier work showed an LA-mediated activation of AMPK in hepatocytes (59) , which is in contrast to a more recent study that reported LA-dependent inhibition on AMPK and reduced autophagy in preadipocytes (60) . PI3K-dependent Akt signaling is another trigger of mTOR activation. Inactivation of Akt by dephosphorylation suppresses mTOR activity, leading to the induction of autophagy. Interestingly, it was reported that LA caused reduced phospho-Akt levels in hepatoma cells (61) . Consistent with this finding, we observed decreased p-Akt levels in HCT116 cells following LA treatment, which is likely to contribute to the induction of autophagy by LA.
To further address the role of autophagy in LA-triggered MGMT depletion, we made use of pharmacological (CQ, Baf A1) and genetic (beclin siRNA) approaches to inhibit autophagy. However, suppression of autophagy at different stages did not abrogate LA-induced MGMT depletion, indicating that autophagy is not involved in MGMT degradation following LA treatment. We also showed that LA-induced MGMT depletion results in higher O 6 -MeG DNA adduct levels induced by the anticancer drug TMZ. Consistent with this finding, pretreatment with LA followed by TMZ treatment resulted in significantly enhanced cell death rates and decreased cell viability compared with single treatments. Finally, we used Balb/c nu/nu mice to establish HCT116 xenografts, which are known for their resistance to O 6 -alkylating agents such as TMZ (45) . In this mouse model, moderate tumour growth retardation was observed in animals treated with LA, and, compared with the TMZ group, significantly smaller tumour volumes were obtained in animals that received LA or the combination of LA and TMZ. Despite these encouraging results, we are aware that the use of LA as a supplement in cancer therapy requires additional studies, e.g. testing other cell lines that are MMR proficient but variable in MGMT, administration routes such as i.v. injection to reach a higher plasma level, or by modulating the treatment scheme.
It is important to note that both HCT116 and RKO cells are deficient in mismatch repair (MMR) (62, 63) , which is essential for O 6 -MeG-triggered cytotoxicity (30, 64) . It is therefore likely that also other LA-mediated effects contribute to the enhanced cytotoxicity observed in these CRC cell lines in combination with TMZ. Thus, LA has recently been shown to trigger caspasedependent and -independent cell death in HCT116 cells at high LA doses and prolonged exposure (23) . We have also observed downregulation of Rad51 by LA, which likely will impact also N-alkylations. Using the same cell lines, it is tempting to speculate that the cytotoxic effects induced by chloroethylating agents such as lomustine will be increased even stronger following LA-induced MGMT depletion, since they do not require functional MMR (65) .
In conclusion, we showed for the first time that LA inhibits the repair activity of MGMT in vitro and in CRC cells. LA-induced depletion of MGMT was independent of its autophagy stimulation. LA also enhanced the cytotoxicity of the anticancer drug TMZ, which makes it a candidate for a supplement in cancer therapy. Supplementary Figures 1-7 can be found at http://carcin.oxfordjournals.org/ 
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